Journal of Neurology

, Volume 258, Issue 6, pp 1046–1054 | Cite as

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study

  • Heike Benes
  • Wolfgang Mattern
  • Ines Peglau
  • Tillmann Dreykluft
  • Lars Bergmann
  • Corinna Hansen
  • Ralf Kohnen
  • Norbert Banik
  • S. W. Schoen
  • Magdolna Hornyak
Original Communication


Comorbid depressive symptoms in restless legs syndrome (RLS) remain a treatment challenge, as some antidepressants aggravate RLS symptoms. Preliminary data in depressive patients suggest antidepressant properties of ropinirole. The present study investigates the effects of ropinirole immediate release (IR) on depressive symptoms and RLS severity. A multicenter, placebo-controlled, double-blind randomized (3:1) study was performed including patients with moderate to severe idiopathic RLS and at least mild depressive symptoms. Ropinirole IR (in flexible doses up to 4 mg/day) or placebo was given for 12 weeks including an uptitration phase of 7 weeks. Visits were scheduled at screening, baseline, and weeks 1, 4, and 12 with additional telephone contacts for dosing decisions. The modified intent to treat population comprised 231 patients (171 ropinirole, 60 placebo). The MADRS (Montgomery–Asberg Depression Rating Scale) scores decreased from baseline to week 12 from 18.8 to 8.7 in the ropinirole group and from 18.4 to 12.1 in the placebo group (primary endpoint, adjusted mean treatment difference −3.6 (95% CI: −5.6 to −1.6, significance in favor of ropinirole: P < 0.001). The superiority of ropinirole compared to placebo was confirmed by the Hamilton Scale for Depression and Beck Depression Inventory-II scores. RLS severity scores (IRLS) decreased by 14.7 (ropinirole) and by 9.9 (placebo, P < 0.001) points. Three out of four subdomains of the Medical Outcomes Study Sleep Scale improved significantly. The findings indicate that mild to moderate depressive symptoms should not be treated before sufficient therapy for RLS. Antidepressant medication can be necessary if depression symptoms still persist even if RLS symptoms are ameliorated.


Restless legs syndrome Depressive symptoms Ropinirole Treatment RCT 



The study was sponsored by GlaxoSmithKline Research and Development and GlaxoSmithKline Germany.

Conflict of interest

HB received honoraria and/or lecture fees from Boehringer Ingelheim, Germany; GlaxoSmithKline, Germany; Pfizer, Germany; Axxonis, Germany; Roche, Germany; UCB, Germany; Jazzpharma, USA. MH received honoraria and/or lecture fees from Boehringer Ingelheim, Germany; GlaxoSmithKline, Germany; Roche, Germany; Pfizer Inc., Germany. RK received honoraria for advisory board membership from Pfizer, Germany; Axxonis, Germany; Roche, Germany; UCB, Germany; Jazzpharma, USA. WM received honoraria and/or lecture fees from GlaxoSmithKline, Germany; Pfizer, Germany; Novartis, Germany; Schwabe, Germany; MSD, Germany; Sanofi, Germany; UCB, Germany; Bayer, Germany; Astra Zeneca, Germany; Lilly, Germany; Janssen-Cilag, Germany; Lundbeck, Germany; Neurochem, Canada; Bristol-Myers-Squibb, Germany; Boehringer Ingelheim, Germany. IP received honoraria and/or lecture fees from AstraZeneca, Germany; Aventis, Germany; Axxonis, Germany; Biogen, Germany; Boehringer Ingelheim, Germany; GlaxoSmithKline, Germany; Janssen-Cilag, Lundbeck, Germany; Novartis, Germany; Pfizer, Germany; Roche, Germany; Takeda, Germany; Teva, Germany; UCB, Germany. TD has no conflict of interest to declare. CH, NB, SWS, and LB are employees of GlaxoSmithKline GmbH & Co. KG.

Supplementary material

415_2010_5879_MOESM1_ESM.ppt (40 kb)
Supplementary material 1 (PPT 40 kb)


  1. 1.
    Allen RP, Picchietti D, Hening WA et al (2003) Restless legs syndrome: diagnostic criteria, special considerations and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 4:101–119PubMedCrossRefGoogle Scholar
  2. 2.
    Berger K, Kurth T (2007) RLS epidemiology-frequencies, risk factors and methods in population studies. Mov Disord 22(suppl18):S420–S423PubMedCrossRefGoogle Scholar
  3. 3.
    Abetz L, Allen R, Follet A et al (2004) Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 26:925–935PubMedCrossRefGoogle Scholar
  4. 4.
    Allen RP, Walters AS, Montplaisir J et al (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165:1286–1292PubMedCrossRefGoogle Scholar
  5. 5.
    Happe S, Reese JP, Stiasny-Kolster K et al (2009) Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 10(3):295–305PubMedCrossRefGoogle Scholar
  6. 6.
    Vandeputte M, deWeerd A (2003) Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 4:343–345PubMedCrossRefGoogle Scholar
  7. 7.
    Ulfberg J, Nyström B, Carter N et al (2001) Prevalence of restless legs syndrome among men aged 18–64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 16:1159–1163PubMedCrossRefGoogle Scholar
  8. 8.
    Winkelmann J, Prager M, Lieb R et al (2005) “Anxietas Tibiarum” depression and anxiety disorders in patients with restless legs syndrome. J Neurol 252:67–71PubMedCrossRefGoogle Scholar
  9. 9.
    Lee HB, Hening WA, Allen RP et al (2008) Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 20:101–105PubMedCrossRefGoogle Scholar
  10. 10.
    Katon W, Lin EH, Kroenke K (2007) The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29(2):147–155PubMedCrossRefGoogle Scholar
  11. 11.
    Hornyak M, Kopasz M, Berger M et al (2005) Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry 66:1139–1145PubMedCrossRefGoogle Scholar
  12. 12.
    Rottach KG, Schaner BM, Kirch MH et al (2008) Restless legs syndrome as side effect of second generation antidepressants. J Psychiatry Res 43:70–75CrossRefGoogle Scholar
  13. 13.
    Picchietti D, Winkelmann JD (2005) Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 28:891–898PubMedGoogle Scholar
  14. 14.
    Cohrs S, Rodenbeck A, Hornyak M, Kunz D (2008) Restless legs syndrome, periodic limb movements and psychopharmacology. Nervenarzt 79(11):1263–1272PubMedCrossRefGoogle Scholar
  15. 15.
    Vignatelli L, Billiard M, Clarenbach P et al (2006) EFNS task force. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13:1049–1065PubMedCrossRefGoogle Scholar
  16. 16.
    Oertel WH, Trenkwalder C, Zucconi M et al (2007) State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 22(suppl18):S466–S475PubMedCrossRefGoogle Scholar
  17. 17.
    Trenkwalder C, Hening WA, Montagna P et al (2008) Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23(16):2267–2302PubMedCrossRefGoogle Scholar
  18. 18.
    Trenkwalder C, Garcia -Borreguero D, Montagna P, On behalf of the TREAT RLS 1 (Therapy with Ropinirole; Efficacy And Tolerability in RLS 1) study group et al (2004) Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75:92–97PubMedGoogle Scholar
  19. 19.
    Walters A, Ondo W, Dreykluft T, On behalf of the TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) study group et al (2004) Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19(12):1414–1423PubMedCrossRefGoogle Scholar
  20. 20.
    Allen R, Becker PM, Bogan R et al (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27(5):907–914PubMedGoogle Scholar
  21. 21.
    Bogan RK, Fry JM, Schmidt MH, For the TREAT RLS US (Therapy with ropinirole And Efficacy, Tolerability in RLS US) study group et al (2006) Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81:17–27PubMedCrossRefGoogle Scholar
  22. 22.
    Perugi G, Toni C, Ruffolo G et al (2001) Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 34(4):137–141PubMedCrossRefGoogle Scholar
  23. 23.
    Cassano P, Lattanzi L, Fava M et al (2005) Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 50(6):357–360PubMedGoogle Scholar
  24. 24.
    Benes H, Kohnen R (2009) Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med 10(5):515–523PubMedCrossRefGoogle Scholar
  25. 25.
    Walters A, The International Restless Legs Syndrome Study Group (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4:121–132PubMedCrossRefGoogle Scholar
  26. 26.
    Montgomery SA, Asberg M (1979) A new depression rating scale designed to be sensitive to change. Brit J Psychiatry 134:382–389CrossRefGoogle Scholar
  27. 27.
    Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(suppl 20):22–33PubMedGoogle Scholar
  28. 28.
    Zimmerman M, Posternak MA, Chelminski I (2004) Defining remission on the Montgomery-Asberg depression rating scale. J Clin Psychiatry 65(2):63–68CrossRefGoogle Scholar
  29. 29.
    Uher R, Farmer A, Maier W et al (2008) Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 38:289–300PubMedCrossRefGoogle Scholar
  30. 30.
    Beck AT, Steer RA, Brown GK (1996) Manual for the Beck depression inventory-II. Psychological corporation, San AntonioGoogle Scholar
  31. 31.
    Frank E, Prien RF, Jarrett RB et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855PubMedGoogle Scholar
  32. 32.
    Hays RD, Martin SA, Sesti AM et al (2005) Psychometric properties of the medical outcomes study sleep measure. Sleep Med 6:41–44PubMedCrossRefGoogle Scholar
  33. 33.
    Hornyak M, Benes H, Eisensehr I, Haan J, Kassubek J, Peglau I, Stiasny-Kolster K, Trenkwalder C (2009) Depression in restless legs syndrome, pathogenesis, assessment, and implications for treatment. Nervenarzt 80(10):1160–1168PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Heike Benes
    • 1
  • Wolfgang Mattern
    • 2
  • Ines Peglau
    • 3
  • Tillmann Dreykluft
    • 4
  • Lars Bergmann
    • 5
  • Corinna Hansen
    • 5
  • Ralf Kohnen
    • 6
    • 7
  • Norbert Banik
    • 5
  • S. W. Schoen
    • 5
  • Magdolna Hornyak
    • 8
  1. 1.Somni-Bene Institute for Medical Research and Sleep MedicineSchwerinGermany
  2. 2.BochumGermany
  3. 3.BerlinGermany
  4. 4.Klinische Forschung BerlinBerlinGermany
  5. 5.GlaxoSmithKline GmbH & CO. KGMunichGermany
  6. 6.RPS Research Germany GmbHNurembergGermany
  7. 7.Department of PsychologyUniversity Erlangen-NurembergNurembergGermany
  8. 8.Interdisciplinary Pain CenterUniversity Medical CenterFreiburgGermany

Personalised recommendations